Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators

Konstantinos Tsiakos, Antonios Tsakiris, Georgios Tsibris, Pantazis Voutsinas, Periklis Panagopoulos, Maria Kosmidou, Vasileios Petrakis, Areti Gravvani, Theologia Gkavogianni, Eleftherios Klouras, Konstantina Katrini, Panagiotis Koufargyris, Iro Rapti, Athanassios Karageorgos, Emmanouil Vrentzos, Christina Damoulari, Vagia Zarkada, Chrysanthi Sidiropoulou, Sofia Artemi, Androniki Papapostolou, Evangelos Michelakis, Maria Georgiopoulou, Dimitra-Melia Myrodia, Panteleimon Tsiamalos, Konstantinos Syrigos, George Chrysos, Thomas Nitsotolis, Haralampos Milionis, Garyphallia Poulakou, Evangelos J. Giamarellos-Bourboulis
doi: https://doi.org/10.1101/2020.12.22.20248753
Konstantinos Tsiakos
1rd, 115 27 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonios Tsakiris
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgios Tsibris
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pantazis Voutsinas
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Periklis Panagopoulos
3nd, 681 00 Alexandroupolis, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Kosmidou
4st, 455 00 Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vasileios Petrakis
3nd, 681 00 Alexandroupolis, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Areti Gravvani
1rd, 115 27 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theologia Gkavogianni
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleftherios Klouras
4st, 455 00 Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantina Katrini
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Panagiotis Koufargyris
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iro Rapti
4st, 455 00 Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athanassios Karageorgos
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanouil Vrentzos
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina Damoulari
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vagia Zarkada
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chrysanthi Sidiropoulou
5nd, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sofia Artemi
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Androniki Papapostolou
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evangelos Michelakis
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Georgiopoulou
2th, 124 62 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimitra-Melia Myrodia
1rd, 115 27 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Panteleimon Tsiamalos
5nd, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantinos Syrigos
1rd, 115 27 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Chrysos
5nd, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Nitsotolis
1rd, 115 27 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haralampos Milionis
4st, 455 00 Ioannina, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Garyphallia Poulakou
1rd, 115 27 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evangelos J. Giamarellos-Bourboulis
1rd, 115 27 Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: egiamarel{at}med.uoa.gr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Clarithromycin clinical efficacy has not been described in COVID-19.

Research question Is oral clarithromycin beneficial for treating patients diagnosed with COVID-19?

Study and methods An open-label non-randomized trial in 90 patients with COVID-19 of moderate severity was conducted at four study sites in Greece between May and October 2020. Ninety participants with respiratory tract infections received clarithromycin 500 mg every 12 hours for 7 days; another 90 standard-of-care (SOC) propensity score-matched concurrent controls received azithromycin plus hydroxychloroquine. The composite primary endpoint was defined for patients with upper respiratory tract infection as: (a) no need for hospital re-admission or (b) lack of progression into lower respiratory tract infection and, for patients with lower respiratory tract infection, as at least 50% decrease of the score of respiratory symptoms at the end-of-treatment (EOT) without progression into severe respiratory failure (SRF). The incidence SRF at the test-of-cure (TOC) on day 14 was a secondary endpoint. For clarithromycin-treated patients, viral load of SARS-CoV-2, biomarkers, the function of mononuclear cells, and safety were assessed; biomarkers were also measured in SOC comparators.

Results The primary endpoint was attained in 86.7% of patients treated with clarithromycin (95% CIs 78.1-92.2%) and 73.3% of concurrent SOC comparators (95%CIs; 63.4-81.4%). The odds ratio for the primary endpoint with clarithromycin treatment in univariate analysis was 2.36 (95%CIs 1.09-5.08; P: 0.039). Results were confirmed after multivariate stepwise logistic regression analysis (odds ratio 3.30; 95% CI 1.10-9.87; P: 0.033). At the TOC visit, the incidence of SRF was 12.2% (n = 11 ; 95%CIs 6.9-20.6%) among patients treated with clarithromycin (odds ratio for SRF 0.38; 95%CIs 0.17-0.84) versus 26.7% (n= 24; 95%CIs 18.6-36.6%) among concurrent SOC comparators (P: 0.023). Clarithromycin use was associated with decreases in circulating levels of C-reactive protein, of tumour necrosis factor-alpha and of interleukin (IL)-6; by an increase of the ratio of Th1 to Th2 mononuclear responses; and by suppression of SARS-CoV-2 relative viral load. No safety concerns were reported. Patients starting clarithromycin with the first five days from symptoms onset achieved better responses.

Interpretation Clarithromycin treatment is associated with early clinical improvement in patients with moderate COVID-19. Modulation of the Th1/Th2 responses is proposed as the mechanism of action.

Trial Registration ClinicalTrials.gov, NCT04398004

Competing Interest Statement

P. Panagopoulos has received honoraria from GILEAD Sciences, Janssen, and MSD. G. Poulakou has received independent educational grants from Pfizer, MSD, Angelini, and Biorad. H. Milionis reports receiving honoraria, consulting fees and non-financial support from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer, and Servier. E.J. Giamarellos-Bourboulis has received honoraria from Abbott CH, Angelini Italy, InflaRx GmbH, MSD Greece, XBiotech Inc., and BRAHMS GmbH (Thermo Fisher Scientific); independent educational grants from AbbVie Inc, Abbott CH, Astellas Pharma Europe, AxisShield, bioMerieux Inc, Novartis, InflaRx GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). The other authors do not report any conflict of interest.

Clinical Trial

NCT04398004

Funding Statement

The study was funded by Abbott Product Operations AG.Funding bodies had no role in the design, conduct, analysis and interpretation of data, and decision to publish.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

EudraCT number 2020-001882-36; National Ethics Committee approval 45/20; National Organization for Medicines approval ISO 36/20; ClinicalTrials.gov registration NCT04398004

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Date are available from the corresponding author on request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted December 26, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators
Konstantinos Tsiakos, Antonios Tsakiris, Georgios Tsibris, Pantazis Voutsinas, Periklis Panagopoulos, Maria Kosmidou, Vasileios Petrakis, Areti Gravvani, Theologia Gkavogianni, Eleftherios Klouras, Konstantina Katrini, Panagiotis Koufargyris, Iro Rapti, Athanassios Karageorgos, Emmanouil Vrentzos, Christina Damoulari, Vagia Zarkada, Chrysanthi Sidiropoulou, Sofia Artemi, Androniki Papapostolou, Evangelos Michelakis, Maria Georgiopoulou, Dimitra-Melia Myrodia, Panteleimon Tsiamalos, Konstantinos Syrigos, George Chrysos, Thomas Nitsotolis, Haralampos Milionis, Garyphallia Poulakou, Evangelos J. Giamarellos-Bourboulis
medRxiv 2020.12.22.20248753; doi: https://doi.org/10.1101/2020.12.22.20248753
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators
Konstantinos Tsiakos, Antonios Tsakiris, Georgios Tsibris, Pantazis Voutsinas, Periklis Panagopoulos, Maria Kosmidou, Vasileios Petrakis, Areti Gravvani, Theologia Gkavogianni, Eleftherios Klouras, Konstantina Katrini, Panagiotis Koufargyris, Iro Rapti, Athanassios Karageorgos, Emmanouil Vrentzos, Christina Damoulari, Vagia Zarkada, Chrysanthi Sidiropoulou, Sofia Artemi, Androniki Papapostolou, Evangelos Michelakis, Maria Georgiopoulou, Dimitra-Melia Myrodia, Panteleimon Tsiamalos, Konstantinos Syrigos, George Chrysos, Thomas Nitsotolis, Haralampos Milionis, Garyphallia Poulakou, Evangelos J. Giamarellos-Bourboulis
medRxiv 2020.12.22.20248753; doi: https://doi.org/10.1101/2020.12.22.20248753

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13340)
  • Forensic Medicine (19)
  • Gastroenterology (897)
  • Genetic and Genomic Medicine (5130)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3253)
  • Health Policy (1138)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1014)
  • Infectious Diseases (except HIV/AIDS) (14613)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4901)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2516)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (540)
  • Pediatrics (1298)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4193)
  • Public and Global Health (7482)
  • Radiology and Imaging (1702)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (546)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)